Edesa Biotech 

$5.55
11
+$0.32+6.12% Wednesday 20:00

Statistics

Day High
6.19
Day Low
5.27
52W High
9.37
52W Low
0.72
Volume
517,682
Avg. Volume
4,355,988
Mkt Cap
46.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.54
-0.44
-0.35
-0.25
Expected EPS
-0.26
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-14.37MNet Income

Analyst Ratings

$5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EDSA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is involved in developing mRNA-based therapies, a field that overlaps with Edesa Biotech's focus on innovative treatments, making them direct competitors in the biotech space.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the development of novel therapies, including mRNA vaccines and treatments, directly challenging Edesa Biotech's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a leader in biopharmaceuticals, focusing on immunology and inflammation, areas that Edesa Biotech is also targeting.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company with a strong presence in antiviral drugs and treatments for inflammatory and respiratory diseases, competing with Edesa Biotech's research focus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm with a broad portfolio, including treatments for inflammatory diseases, which puts it in competition with Edesa Biotech's therapeutic areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in similar therapeutic areas as Edesa Biotech, including immunology and chronic diseases, making them competitors in the biopharmaceutical field.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company with a wide range of products, including vaccines and biologics that compete with Edesa Biotech's developments.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that overlap with Edesa Biotech's focus areas, particularly in immunology.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company with a strong emphasis on research and development in areas like dermatology and rheumatology, competing with Edesa Biotech.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a diverse biopharmaceutical portfolio, including treatments for respiratory and autoimmune diseases, making it a competitor to Edesa Biotech.

About

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Show more...
CEO
Dr. Pardeep Nijhawan FRCPC, M.D.
Employees
16
Country
CA
ISIN
CA27966L3065

Listings

0 Comments

Share your thoughts

FAQ

What is Edesa Biotech stock price today?
The current price of EDSA is $5.55 USD — it has increased by +6.12% in the past 24 hours. Watch Edesa Biotech stock price performance more closely on the chart.
What is Edesa Biotech stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Edesa Biotech stocks are traded under the ticker EDSA.
Is Edesa Biotech stock price growing?
EDSA stock has fallen by -5.29% compared to the previous week, the month change is a +143.42% rise, over the last year Edesa Biotech has showed a +126.53% increase.
What is Edesa Biotech market cap?
Today Edesa Biotech has the market capitalization of 46.25M
When is the next Edesa Biotech earnings date?
Edesa Biotech is going to release the next earnings report on May 08, 2026.
What were Edesa Biotech earnings last quarter?
EDSA earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.53 USD resulting in a +46.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Edesa Biotech revenue for the last year?
Edesa Biotech revenue for the last year amounts to 0 USD.
What is Edesa Biotech net income for the last year?
EDSA net income for the last year is -14.37M USD.
How many employees does Edesa Biotech have?
As of April 02, 2026, the company has 16 employees.
In which sector is Edesa Biotech located?
Edesa Biotech operates in the Health Care sector.
When did Edesa Biotech complete a stock split?
The last stock split for Edesa Biotech was on October 11, 2023 with a ratio of 1:7.
Where is Edesa Biotech headquartered?
Edesa Biotech is headquartered in Markham, CA.